Transcriptomic data made use of within this publication has been deposited in NCBI
Transcriptomic data made use of within this publication has been deposited in NCBI’s Gene Expression Omnibus (Nia et al., 2020) and are accessible through GEO Series accession number GSE136165 (, (accessed on 29 October 2021). Acknowledgments: We would prefer to acknowledge William Russell Director of the UTMB Proteomics Core (the UTMB Mass Spectrometry Facility is supported in element by CPRIT grant no. RP190682 (W.K.R.) and Steven Widen Director on the UTMB Next Generation Sequencing Core for all their assist and experience with data acquisition for both the proteomics and transcriptomics and their willingness to normally answer concerns and present feedback. We would like to acknowledge Alex Tan of Galveston Ball Higher School for each of the function that she did on this project through her Bench Student Plan in Emmett’s laboratory. We would also like to give unique due to the NSRL Physicists, Michael SSTR2 Agonist supplier Sivertz, Chiara La Tessa, I-Hung Chiang, and Adam Rusek; the NSRL Support, Angela Kim, Paula Bennett, James Jardine, Leah Selva, and Peter Guida; the BLAF Group: Debbie Snyder, Kerry Bonti, Corinne Baran, and MaryAnn Petry; and other individuals in the BNL, for HZE beamline access and help with animal care and irradiations. Conflicts of Interest: The authors have no conflict of interest to declare.
Iranian Journal of Pharmaceutical Study (2021), 20 (3): 381-398 DOI: 10.22037/ijpr.2021.114785.15032 Received: December 2020 Accepted: FebruaryOriginal ArticleSelf-emulsifying Drug Delivery Technique for Enhanced P2X7 Receptor Agonist Formulation dissolution and Oral Absorption of Quetiapine Fumarate: Investigation of Drug Release Mechanism and In-vitro Intestinal PermeabilityOlfa Ben Hadj Ayed , Mohamed Ali Lassoued, Badr Bahloul and Souad SfarLaboratory of Pharmaceutical, Chemical and Pharmacological Drug Development LR12ES09, Faculty of Pharmacy, University of Monastir, Avicenne Street, 5000 Monastir, Tunisia. Abstract In this study, we focused on quetiapine fumarate (QTF), a class II BCS drug. QTF is an atypical antipsychotic utilized within the remedy of schizophrenia and bipolar problems. Our objective was to develop a new QTF-loaded self-emulsifying drug delivery system (SEDDS) to improve the dissolution and absorption of the drug. An experimental design and style strategy was used to develop and optimize QTF-loaded SEDDS. The optimized formulation was characterized for droplets size, zeta prospective, PDI, and stability. It was then evaluated applying an in-vitro combined test for dissolution and Everted gut sac technique. Mathematical modeling and Transmission electron microscopy (TEM) were used to elucidate the mechanism of release. The optimal formulation was form IIIB SEDDS, constituted of 9.1 of oleic acid, 51.6 of Tween0, and 39.three of TranscutolP. It showed a droplets size of 144.eight four.9nm with an acceptable PDI and zeta potential. For in-vitro evaluation tests, we noticed an enhancement of your dissolution rate of the optimal QTF-loaded SEDDS when compared with the totally free drug (98.82 1.24 for SEDDS right after 30 min compared to 85.65 2.five for the pure drug). The release of QTF fitted together with the Hopfenberg model indicating the drug was released by water diffusion and erosion mechanism. This result was confirmed by TEM pictures which showed a smaller sized droplet size following release. We also identified an amelioration from the permeability of QTF of 1.69-fold from SEDDS when compared with the free drug. Hence, the SEDDS formulation represented a new way to strengthen the dissolution and absorption of QTF. Ke.